GLP1R and diabetic kidney disease: Future research should prioritize exploring optimal combination regimens of GLP-1 receptor agonists with the novel mineralocorticoid receptor antagonist finerenone, aiming to develop superior multi-target intervention strategies for diabetic nephropathy.